This article is a correction to:
Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review
Truong Van Dat1
Vo Linh Tu2
Le Nguyen Anh Thu1Nguyen Nhat Anh Quang1Van Binh1Nguyen Thi Quynh Nga1
Duong Hoang Loc1Tran Thi Hong Nguyen1
Dao Ngoc Hien Tam3
Hong-Han Huynh4
Tran Dinh Trung5
Uyen Do6
Nguyen Tuan Phat7Dang The Hung8
Quang-Hien Nguyen7
Nguyen Thi Hai Yen1*
Le Huu Nhat Minh9,10*- 1Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
- 2Faculty of Traditional Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
- 3Regulatory Affairs Department, Asia Shine Trading & Service Co. Ltd., Ho Chi Minh City, Vietnam
- 4International Master Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
- 5Faculty of Public Health, Danang University of Medical Technology and Pharmacy, Danang, Vietnam
- 6Nelda C. Stark School of Nursing, Texas Woman’s University, Houston, TX, United States
- 7Cardiovascular Research Department, Methodist Hospital, Merrillville, IN, United States
- 8School of Biomedical Engineering & Imaging Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom
- 9International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- 10Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei, Taiwan
A Corrigendum on
Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review
by Dat TV, Tu VL, Thu LNA, Quang NNA, Binh V, Nga NTQ, Loc DH, Nguyen TTH, Tam DNH, Huynh H-H, Trung TD, Do U, Phat NT, Hung DT, Nguyen Q-H, Yen NTH and Minh LHN (2024). Front. Pharmacol. 14:1156655. doi: 10.3389/fphar.2023.1156655
In the published article, there was an error in Affiliation 1. Instead of “Department of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh city, Vietnam,” it should be “Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.”
In the published article, there was an error regarding the Affiliation for Tran Dinh Trung. Instead of “Department of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh city, Vietnam”, it should be “Faculty of Public Health, Danang University of Medical Technology and Pharmacy, Danang, Vietnam.”
In the published article, there was an error.
A correction has been made to Results, Main results, Safety, Paragraph Number 1. This paragraph previously stated:
“There were 14 studies that reported the safety of perindopril/amlodipine FDC (Supplementary Table S2). Of these, several serious but rare emergent adverse events (EAEs) of perindopril/amlodipine FDC have been reported, including stroke, brain infarction, cataracts, and diaphragmatic eventration (Hu et al., 2016). In the study by Fleig et al., eight patients (0.4%) experienced severe EAEs in 140 ADR of 88 patients, of which four patients (0.2%) did not recover and one patient died with a hypertensive crisis (Fleig et al., 2018).”
The corrected sentence appears below:
“There were 14 studies that reported the safety of perindopril/amlodipine FDC (Supplementary Table S2). Hu et al. reported emergent adverse events (EAEs) of perindopril/amlodipine FDC, including stroke (one patient), synovitis (one patient), pregnancy (one patient), cataracts (one patient), and diaphragmatic complications (one patient). While serious EAEs in the comparator drug group included lumbar intervertebral disc protrusion (one patient), cerebral infarction (one patient), and lacunar infarction (one patient) (Hu et al., 2016). In the study by Fleig et al., only eight patients (0.4%) experienced severe EAEs in 140 ADR of 88 patients, of which four patients (0.2%) did not recover and one patient died with a hypertensive crisis (Fleig et al., 2018).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: fixed-dose combination, hypertension, blood pressure, efficacy, perindopril, amlodipine, effectiveness
Citation: Van Dat T, Tu VL, Thu LNA, Quang NNA, Binh V, Nga NTQ, Loc DH, Nguyen TTH, Ngoc Hien Tam D, Huynh H-H, Trung TD, Do U, Phat NT, Hung DT, Nguyen Q-H, Yen NTH and Minh LHN (2024) Corrigendum: Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review. Front. Pharmacol. 15:1426608. doi: 10.3389/fphar.2024.1426608
Received: 01 May 2024; Accepted: 13 May 2024;
Published: 04 June 2024.
Edited and reviewed by:
Heike Wulff, University of California, Davis, United StatesCopyright © 2024 Van Dat, Tu, Thu, Quang, Binh, Nga, Loc, Nguyen, Ngoc Hien Tam, Huynh, Trung, Do, Phat, Hung, Nguyen, Yen and Minh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nguyen Thi Hai Yen, aGFpeWVuQHVtcC5lZHUudm4=; Le Huu Nhat Minh, bGVodXVuaGF0bWluaEBnbWFpbC5jb20=